Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for...

First Canadian Participant Dosed in ARGUS Trial, A Phase 2 Potentially Pivotal Study of EPX-100 Treatment of Dravet Syndrome PARAMUS, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company focused on genetically screening, discovering and developing safe, effective and...

Epygenix Therapeutics Announces Appointment of Dr. Lorianne Masuoka as Chief Medical Officer PARAMUS, N.J., May 23, 2022 (GLOBE NEWSWIRE) -- Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable...